DK0699076T3 - Vaccine mod mellemørebetændelse - Google Patents

Vaccine mod mellemørebetændelse

Info

Publication number
DK0699076T3
DK0699076T3 DK94922428T DK94922428T DK0699076T3 DK 0699076 T3 DK0699076 T3 DK 0699076T3 DK 94922428 T DK94922428 T DK 94922428T DK 94922428 T DK94922428 T DK 94922428T DK 0699076 T3 DK0699076 T3 DK 0699076T3
Authority
DK
Denmark
Prior art keywords
fimbrin
vaccine
middle ear
ear inflammation
dna coding
Prior art date
Application number
DK94922428T
Other languages
Danish (da)
English (en)
Inventor
Tatiana Sirakova
Pappachan E Kolattukudy
Lauren O Bakaletz
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of DK0699076T3 publication Critical patent/DK0699076T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94922428T 1993-05-18 1994-05-12 Vaccine mod mellemørebetændelse DK0699076T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6544293A 1993-05-18 1993-05-18
PCT/US1994/005477 WO1994026304A1 (en) 1993-05-18 1994-05-12 Otitis media vaccine

Publications (1)

Publication Number Publication Date
DK0699076T3 true DK0699076T3 (da) 2003-03-03

Family

ID=22062752

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94922428T DK0699076T3 (da) 1993-05-18 1994-05-12 Vaccine mod mellemørebetændelse

Country Status (9)

Country Link
US (3) US5766608A (de)
EP (2) EP1300156A3 (de)
JP (1) JP3429313B2 (de)
AT (1) ATE226831T1 (de)
DE (1) DE69431624T2 (de)
DK (1) DK0699076T3 (de)
ES (1) ES2185658T3 (de)
PT (1) PT699076E (de)
WO (1) WO1994026304A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
EP0702516A4 (de) * 1993-06-01 1998-04-22 Life Technologies Inc Genetische immunisierung mit kationischen lipiden
US5770213A (en) 1994-05-05 1998-06-23 American Cyanamid Company Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
EP1524991A1 (de) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Impfstoffzusammensetzung die transferrin bindende protein und hsf aus gram-negativen bakterien enthält
EP2395073B1 (de) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Trockungsverfahren
DE602004028262D1 (de) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
DE602006018308D1 (de) * 2005-07-08 2010-12-30 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae-induzierte infektion
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2007206114B2 (en) 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
EP2250286A1 (de) 2008-02-15 2010-11-17 Life Technologies Corporation Verfahren und zusammensetzungen zum scheren von polymeren mittels ultraschallbehandlung
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2544714A1 (de) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Impfstoffzusammensetzung
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
US9855326B2 (en) 2013-03-08 2018-01-02 Research Institute At Nationwide Children's Hospital Transcutaneous haemophilus influenzae vaccine formulations and methods
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5110908A (en) * 1986-12-31 1992-05-05 Praxis Biologics, Inc. Haemophilus influenzae peptides and proteins
ES2185658T3 (es) 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.

Also Published As

Publication number Publication date
EP1300156A3 (de) 2003-05-07
JP3429313B2 (ja) 2003-07-22
WO1994026304A1 (en) 1994-11-24
PT699076E (pt) 2003-03-31
ATE226831T1 (de) 2002-11-15
DE69431624T2 (de) 2003-07-10
ES2185658T3 (es) 2003-05-01
EP0699076A4 (de) 1999-09-08
JPH09500104A (ja) 1997-01-07
EP0699076A1 (de) 1996-03-06
US5766608A (en) 1998-06-16
US6030626A (en) 2000-02-29
EP1300156A2 (de) 2003-04-09
DE69431624D1 (de) 2002-12-05
EP0699076B1 (de) 2002-10-30
US6562349B1 (en) 2003-05-13

Similar Documents

Publication Publication Date Title
DK0699076T3 (da) Vaccine mod mellemørebetændelse
NO953033L (no) Stabile baktericid/permeabilitetsökende proteinprodukter og farmasöytiske preparater inneholdende disse
HUP9801638A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló proteáz K variánsok
ATE389666T1 (de) Hohe expressionsrate von proteinen
AU3509995A (en) Overexpression of mammalian and viral proteins
ATE189477T1 (de) Mutierte penicillin-g-acylase gene
HUP9800765A2 (hu) Kevésbé adszorbeálódó és fokozottan hidrolizáló szubtilizin Carlsberg variánsok
DE69129604D1 (de) Mutierte beta-Lactamacylasegene
ATE262038T1 (de) Br96 mutantantikörper die mit menschlichen karzinomen reagieren
ATE64619T1 (de) Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli.
IL115242A0 (en) Recombinant mersacidin and a method for production
HUP9800767A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló szubtilizin DY variánsok
AU8258591A (en) Human mk gene and protein sequence
ATE248918T1 (de) Rekombinante dnase b aus streptococcus pyogenes
WO2000001831A3 (en) Proteases fused with variants of streptomyces subtilisin inhibitor
HUP9802069A2 (hu) Kevésbé adszorbeálódó és jobban hidrolizáló termitáz variánsok
EP1251176A3 (de) Expressionssysteme, die selbstspaltende Fusionsproteine verwenden sowie ein reduzierendes Polypeptid
WO1995013386A3 (en) Tyrosinase-activator protein fusion enzyme
WO2001044289A3 (en) Modified leukotoxin gene and protein
AU4568496A (en) Acarbose biosynthesis genes from Actinoplanes sp., process for the isolation thereof and the use thereof
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
AU5260801A (en) Novel (r)-2-hydroxy-3-phenylpropionate (d-phenyllactate) dehydrogenase and gene encoding the same
DE60021707D1 (de) Beta-primeverosidase gen
WO2002026817A3 (en) 33521, a human guanine nucleotide exchange family member and uses thereof
DK0663955T3 (da) Nucleinsyre, som koder for en alfa-acetolactat-decarboxylase, og anvendelser deraf